# Junta clínica — PT-pseudo_b63dfe0f311e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b63dfe0f311e",
  "pid": "PT-pseudo_b63dfe0f311e",
  "task": 1,
  "psa": 5.3,
  "age": 67,
  "months": 2,
  "pirads": "2",
  "psad": 0.1,
  "psav": 0.47,
  "psap": 5.1,
  "vol": 50.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.39097,
  "medhx": "Hypertension, Hypercholesterolaemia",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, rosuvastatin",
  "notes": "PSA 5.3 ng/mL. PI-RADS 2. PSAD 0.10. Prostate volume 50 mL. csPCa 0.39.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "68 kg",
    "height": "175 cm",
    "bmi": "22.2",
    "bp": "138/89 mmHg",
    "hr": "85 bpm",
    "smoking": "Ex-smoker (37 pack-yr, quit 2018)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "17 Feb 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing evaluation of elevated prostate-specific antigen levels alongside reassessment after a previous biopsy."
    },
    {
      "s": "History",
      "t": "First noted for a PSA rise in late 2022, this 67-year-old widower has since been tracked by his primary care physician. He works as a retired carpenter residing in an independent retirement community, with his sister designated as next of kin. A 37 pack-year smoking history ends in 2018. Clinical background includes hypertension and hypercholesterolaemia, currently treated with amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and rosuvastatin. He avoids alcohol entirely, swims weekly, and manages mild knee pain stemming from years of manual labour. A cardiology assessment in autumn 2024 confirmed stable cardiovascular health. Urinary symptoms remain minimal, anchored at a baseline IPSS of 9, and he commutes 60 minutes by train for each clinic visit. The clinical picture aligns with a positive prior biopsy bucket."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal. The prostate exhibits a symmetrically enlarged, smooth, and firm consistency without palpable nodules or asymmetry. General examination reveals a well-nourished, alert gentleman in no acute distress. Blood pressure measures 138/89 mmHg, accompanied by a regular heart rate of 85 bpm."
    }
  ],
  "occupation": "retired carpenter",
  "marital": "Widowed",
  "living": "Lives in retirement community (independent unit)",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 9/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "OLVG (Amsterdam)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b63dfe0f311e
Task: 1

Encounter: Urology - outpatient on 17 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 5.3 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.1 ng/mL²
  - PSA velocity: 0.47 ng/mL/yr
  - Prior PSA: 5.1 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.39097 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 5.3 ng/mL. PI-RADS 2. PSAD 0.10. Prostate volume 50 mL. csPCa 0.39.

Vitals: weight 68 kg, height 175 cm, BMI 22.2, BP 138/89 mmHg, HR 85 bpm. Smoking: Ex-smoker (37 pack-yr, quit 2018).

Chief complaint: Ongoing evaluation of elevated prostate-specific antigen levels alongside reassessment after a previous biopsy.

History: First noted for a PSA rise in late 2022, this 67-year-old widower has since been tracked by his primary care physician. He works as a retired carpenter residing in an independent retirement community, with his sister designated as next of kin. A 37 pack-year smoking history ends in 2018. Clinical background includes hypertension and hypercholesterolaemia, currently treated with amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and rosuvastatin. He avoids alcohol entirely, swims weekly, and manages mild knee pain stemming from years of manual labour. A cardiology assessment in autumn 2024 confirmed stable cardiovascular health. Urinary symptoms remain minimal, anchored at a baseline IPSS of 9, and he commutes 60 minutes by train for each clinic visit. The clinical picture aligns with a positive prior biopsy bucket.

Physical examination: DRE: Normal. The prostate exhibits a symmetrically enlarged, smooth, and firm consistency without palpable nodules or asymmetry. General examination reveals a well-nourished, alert gentleman in no acute distress. Blood pressure measures 138/89 mmHg, accompanied by a regular heart rate of 85 bpm.

Patient info: retired carpenter; Widowed; Lives in retirement community (independent unit).
Next of kin: Sibling (sister).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Swimming 1x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.25
  uncertainty  +/- 0.10 epistemic (95% band 0.05-0.45); among patients I cannot tell apart the outcome was 0.81 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PI-RADS 1-2 on the current mpMRI: there is no lesion to sample. In the labelled series this criterion matched the reading urologist in 2 of 2 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.81: PI-RADS 2, PSA 4.7, PSAD 0.14, age 67, DRE Normal -> DEFER (clear). He wrote: "Priads 2 with only sightly elevated PSA"
  2. distance 2.03: PI-RADS 3, PSA 7.7, PSAD 0.11, age 64, DRE Normal -> DEFER (borderline). He wrote: "Low risk PC with PSA <10. No red flags on biopsy or MRI, reasonably low PSA density. MRI finding minor and probably penetrated by systematic biopsy core (peripheral zone…"
  3. distance 2.03: PI-RADS 2, PSA 8.3, PSAD 0.206, age 66, DRE Nodus -> DEFER (clear). He wrote: "Patient with low-risk cancer on active surveillance. Now normal MRI."

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a stable MRI (PI-RADS 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15ng/ml/cc. The guideline recommends offering active surveillance (AS) as standard of care to all suitable patients with low-risk disease and selected patients with favourable intermediate-risk disease.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is contradicted by the cohort criterion which specifically matches this patient's situation as a DEFER criterion based on the PI-RADS 1-2 score. The library precedents suggest a DEFER decision, but the cohort criterion indicates that the decision hinges on the PI-RADS score, which is a fact that overrides the general panel variables.

WHAT WE STILL NEED
The prior-biopsy status is 'Positive', which is a fact that makes it decisive.
The PI-RADS score is '2', which is a fact that makes it decisive.
The PSA density is '0.1', which is a fact that makes it decisive.
The prior biopsy status is 'Positive', which is a fact that makes it decisive.
The PI-RADS score is '2', which is a fact that makes it decisive.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 2 finding, combined with the prior positive biopsy, mandates deferral according to the cohort criterion.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the MRI?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend?
  previous_notes (get_previous_notes) -> What was the prior biopsy result (Gleason/ISUP), and what is the current surveillance plan?
  laboratory_results (get_lab_results) -> What are the full laboratory results, including free-PSA fraction and renal function?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the GRADE (Gleason or ISUP) of the prior biopsy?
  Q2. Is there a surveillance protocol in place, and is a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
OLVG Amsterdam | 10 February 2025 | Multiparametric MRI of the Prostate
The lesion size and zone of the MRI: The gland occupies approximately 50.0 mL. T2 sequences highlight a uniform peripheral zone, entirely free of focal hypointense abnormalities. Mild benign nodular hyperplasia characterizes the transition zone.
psa_trend
The serial PSA value trend: [{"date": "Oct 2022", "val": 0.9}, {"date": "Dec 2023", "val": 1.7}, {"date": "Feb 2025", "val": 5.3}]
previous_notes
The prior biopsy result (Gleason/ISUP), and what is the current surveillance plan: The prior biopsy confirmed Gleason 3+3 disease, and the current surveillance plan is reassessment after a previous biopsy.
laboratory_results
The full laboratory results, including free-PSA fraction and renal function: PSA 5.3 ng/mL on 06 Jan 2025, Free PSA 1.40 ng/mL on 06 Jan 2025, %Free PSA 26% on 06 Jan 2025, eGFR >60 mL/min/1.73m2 on 06 Jan 2025.

WHAT I DID NOT OPEN
family-history anamnesis, because the cohort criterion explicitly stated that the decision hinges on the PI-RADS score, which was already visible.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
Prior biopsy was positive.
PSA velocity is 0.47 ng/mL/yr.

Findings that argue AGAINST sampling this patient now:
PI-RADS score is 2.
The EAU guideline suggests active surveillance is standard of care for low-risk disease.

WHERE THIS LEANS
The evidence points towards deferral based on the PI-RADS 2 finding, which aligns with the cohort criterion and the EAU guideline recommendation for low-risk disease.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 5.30 ng/mL over 3 points spanning 28 months; velocity +1.89 ng/mL per year; doubling time about 11 months.
PROJECTION at 6 months: 7.2 ng/mL, conformal 95% band 2.1-25.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.21
  uncertainty  +/- 0.09 epistemic (95% band 0.03-0.38), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.25  ('firm' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.21  ('firm' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents)
  EXPERT-COHORT      DEFER  (rule pirads_le_2)

  documented prior grade in the opened documents: GG 1 ("Gleason 3+3")

RULE THAT FIRED: cohort criterion (pirads_le_2) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 2 of 2 labelled cases in exactly this situation (prior positive biopsy).

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—have addressed both open questions. The prior biopsy grade (Gleason 3+3) is in previous_notes, and the surveillance plan is mentioned in previous_notes.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, as the cohort criterion (PI-RADS $\le 2$) fired, and the documented prior grade (GG 1) was present in the opened documents.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the GRADE (Gleason or ISUP) of the prior biopsy? Answered by the registrar: "The prior biopsy confirmed Gleason 3+3 disease."
Q2. Is there a surveillance protocol in place, and is a confirmatory biopsy due? Answered by the registrar: "the current surveillance plan is reassessment after a previous biopsy."

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 2 is the most critical variable because it directly triggered the cohort criterion in the panel protocol, which is a strong rule for this situation. The prior positive biopsy status also carried significant weight, as noted by the trace model.

MY SUGGESTION TO THE CHAIR
I suggest the decision should proceed with NO BIOPSY, as the evidence retrieved confirms the panel's conclusion based on the PI-RADS 2 finding and the prior biopsy status.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the cohort criterion, triggered by the PI-RADS 2 finding, strongly supports deferral, which aligns with the EAU guideline for low-risk disease. This conclusion is supported by the documented prior positive biopsy status and the fact that the prior biopsy confirmed Gleason 3+3 disease. The evidence converged on deferral because the PI-RADS 2 score was the most critical variable, overriding other factors.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
